Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 48

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 48
---
 the Related Party Transaction Policy and as such, these transactions were not subject to the approval and review procedures set forth in the policy. However, these transactions were reviewed and approved by our Board, and the Letter Agreement was reviewed and approved in accordance with our Related Party Transaction Policy. Notice of Annual Meeting of Stockholders and 2025 Proxy Statement | 30

TABLE OF CONTENTS

| ​ | EQUITY COMPENSATION PLAN INFORMATION | ​ |

The following table sets forth certain information regarding our equity compensation plans as of December 31, 2024:

| ​ | ​ | Plan Category                                              | ​ | ​ | ​ | Number ofsecurities tobe issuedupon exerciseof outstandingoptions andother rights | ​ | ​ | ​ | Weighted-averageexerciseprice ofoutstandingoptions andother rights(1) | ​ | ​ | ​ | Number of securitiesremaining availablefor future issuanceunder equitycompensation plans(excluding securitiesreflected in column(a)) | ​ | ​ |
| ​ | ​ | ​                                                          | ​ | ​ | ​ |                                                                                -a | ​ | ​ | ​ |                                                                    -b | ​ | ​ | ​ |                                                                                                                                   -c | ​ | ​ |
| ​ | ​ | Equity compensation plans approved by security holders(2)  | ​ | ​ | ​ |                                                                      5,310,229(3) | ​ | ​ | ​ |                                                                 $5.66 | ​ | ​ | ​ |                                                                                                                         4,536,457(4) | ​ | ​ |
| ​ | ​ | Equity compensation plans not approved by security holders | ​ | ​ | ​ |                                                                                 — | ​ | ​ | ​ |                                                                     — | ​ | ​ | ​ |                                                                                                                                    — | ​ | ​ |
| ​ | ​ | Total                                                      | ​ | ​ | ​ |                                                                         5,310,229 | ​ | ​ | ​ |                                                                 $5.66 | ​ | ​ | ​ |                                                                                                                            4,536,457 | ​ | ​ |

(1) Represents the weighted-average exercise price of outstanding stock options. This weighted-average exercise price does not reflect shares subject to outstanding RSUs. (2) Represents shares available for future issues under the 2021 Plan and 2021 Employee Stock Purchase Plan, or the 2021 ESPP. No new grants will be made under our 2018 Equity Incentive Plan. The 2021 Plan contains an “evergreen” provision, pursuant to which, on or about January 1 each year